BioMed Research International · 2013 · 39 citations · 14 references
MedicineCardiologyPharmacologyBiochemical PharmacologyCellular MetabolismMitochondrial BiologyMitochondrial CardiomyopathyMitochondrial DysfunctionMitochondrial PhysiologyMitochondrial SignalingCardiac Mitochondrial FunctionMetabolic ModulationMitochondrial Function In CardiomyocytesMitochondrial Permeability Transition Pore SignalingOxidative Stress In Cardiovascular DiseaseOxidative Stress In DiabetesOxidative Stress InjuryPermeability Transition Pore Opening
Dysfunction of cardiac mitochondria appears to play a substantial role in cardiomyopathy or myocardial dysfunction and is a promising therapeutic target for many cardiovascular diseases. We investigated the effect of the Rho/Rho-associated protein kinase (ROCK) inhibitor fasudil on cardiac mitochondria from rats in which diabetes was induced by a combination of streptozotocin (STZ) and a sustained high-fat diet. Eight weeks after diabetes was induced by a single intraperitoneal injection of 50 mg/kg STZ followed by a sustained high-fat diet, either fasudil (5 mg/kg bid) or equivalent volumes of saline (control) were administered over four weeks. Fasudil significantly protected against the histopathologic changes of cardiac mitochondria in diabetic rats. Fasudil significantly reduced the abundances of the Rho A, ROCK 1, and ROCK 2 proteins, restored the activities of succinate dehydrogenase (SDH) and monoamine oxidase (MAO) in cardiac mitochondria, inhibited the opening of the mitochondrial permeability transition pore, and decreased the total antioxidant capacity, as well as levels of malonyldialdehyde, hydroxy radical, reduced glutathione, and superoxide dismutase in heart. Fasudil improved the structures of cardiac mitochondria and increased both SDH and MAO activities in cardiac mitochondria. These beneficial effects may be associated with the attenuation of oxidative stress caused by fasudil treatment.
14
Mitochondrial Dysfunction and Type 2 Diabetes
Bradford B. Lowell, Gerald I. Shulman · Science · 2005 · 2.1K citations
A new rat model of type 2 diabetes: The fat-fed, streptozotocin-treated rat
Michael Reed, Karl Meszaros, L. J. Entes et al. · Metabolism · 2000 · 848 citations
Medicine, Endocrinology, Physiology +11